ChatGPT Provides Inaccurate Responses to Questions About Drug Information
Drug Topics
DECEMBER 7, 2023
Two posters presented at ASHP 2023 Midyear examined how accurate answers were from the artificial intelligence chatbot.
drug-information 
Opinion: STAT+: Some countries are moving to digital prescription drug information for patients. The U.S. shouldn’t follow suit
STAT
JANUARY 22, 2024
Getting a new prescription can be overwhelming: medication schedules, foods to eat or avoid, interactions between different drugs. Having all of these details in accessible, printed documents keeps patients informed and mitigates the risk of medication errors. Other nations have or are now exploring policies themselves.
Join 18,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
AAM commends HHS, FTC call for information, solutions on drug shortages
Drug Store News
FEBRUARY 19, 2024
A Request For Information asks what impact GPOs and drug wholesalers have on generic medication shortages.
52 
Drug Transparency Can Help Patients Make Better, More Informed Decisions
Drug Topics
OCTOBER 26, 2023
Lathe Bigler, Vice President of Clinical Network Services at FDB and General Manager at FDB Vela, discusses drug transparency and why it's important for patients to shop around for their prescriptions.
98 
STAT+: Afraid of pharma pushback, a health data broker puts up a barrier to drug pricing information
STAT
DECEMBER 1, 2022
At a time when many Americans are clamoring for more transparency into prescription drug pricing, one key provider of that data is making it harder to access the information.
Packaging 90
90 Packaging 90
90 
Approval of Eli Lilly's Alzheimer Drug Donanemab Delayed as FDA Seeks More Information
PharmExec
MARCH 8, 2024
Because of the unique trial design of the Phase III TRAILBLAZER-ALZ 2 study, the FDA is seeking additional input regarding the safety and efficacy of donanemab for the treatment of early symptomatic Alzheimer disease.
FDA 52
52 FDA 52
52 
Exploring the Role of Pharmacists as Facilitators of Harm Reduction Resources
Drug Topics
APRIL 1, 2024
According to Anita Jacobson, pharmacists should actively facilitate access to harm reduction programs by providing information and resources, ensuring the person who uses drugs doesn’t have to navigate the landscape on their own.
187 
Despite positive trial, Roche says Enspryng fell short of expectations in myasthenia gravis
Fierce Pharma
MARCH 21, 2024
Drug developers often try to spot tidbits of positive information from a failed clinical trial. Drug developers often try to spot tidbits of positive information from a failed clinical trial. But Roche is doing the opposite for its positive Enspryng study in the competitive autoimmune disorder of myasthenia gravis.
95 
Ohio Attorney General Sues Express Scripts and Prime Therapeutics For Price Fixing
Drug Topics
MARCH 30, 2023
The suit alleges that Express Scripts, Prime and Prime customer Humana Pharmacy Solutions are able to share drug pricing and rebate information to increase prices for insulins, biologics and cancer drugs.
187 
STAT+: Drug shortages reached a record high as 2023 drew to a close
STAT
APRIL 10, 2024
The number of ongoing and active drug shortages in the U.S. stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country. The reasons are varied, although many remain a mystery.
Chemotherapy 134
134 
AI in Drug Discovery: Day Two
pharmaphorum
APRIL 22, 2024
Discover the innovative use of artificial intelligence (AI) in drug discovery with a focus on GenAI and Large Language Models (LLMs) on Day Two of this informative event. Explore how technology is revolutionising the pharmaceutical industry.
76 
Opinion: The FDA and FTC need to crack down on TikTok and Instagram influencers pitching prescription drugs
STAT
JANUARY 22, 2024
In June, the Food and Drug Administration issued a warning letter about advertisements for the drug Recorlev for Cushing’s syndrome — its first in more than a year about webpages that make “false or misleading claims” about prescription drugs. Read the rest…
FDA 135
135 FDA 135
135 
FDA Tells Congress What It Wants, What it Really Really Wants (it really really really wants a zigazig-ah)
The FDA Law Blog
APRIL 2, 2024
Perhaps unsurprisingly given the extraordinary focus on drug pricing in the last decade, generic competition—FDA’s only real way to have an effect on drug pricing—tops this year’s list. FDA believes this change would effectuate timelier and more cost-efficient generic drug development.”
FDA 104
104 
GLP-1 drugs not linked to suicidal thoughts in FDA’s early review
STAT
JANUARY 11, 2024
A preliminary evaluation by the Food and Drug Administration did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions. A review of trials and studies conducted on the medications also didn’t find a link to suicidal thoughts and actions. Read the rest…
FDA 126
126 FDA 126
126 
Opinion: Personalized medicine: We’re not there yet
STAT
APRIL 5, 2024
By the year 2020, he opined, “gene-based designer drugs are likely to be available for conditions like diabetes, Alzheimer’s disease, hypertension, and many other disorders.
111 
Comparison Of Rebyota Versus Vowst: A Study Table To Help You Compare Fecal Microbiota Therapies
IDStewardship
APRIL 14, 2024
Basic information on Clostridioides difficile infection (CDI), fecal microbiota transplantation (FMT), and a study table comparing Rebyota and Vowst is provided. Infect Drug Resist. O’Connor, Pharm.D., Closing Thoughts CDI is a leading cause of healthcare-associated infection [4]. Gastro Endo News. Seekatz AM, Safdar N, Khanna S.
FDA 324
324 
STAT+: FDA cracks down on websites that claim to sell chemicals in obesity drugs Wegovy, Zepbound
STAT
FEBRUARY 15, 2024
The Food and Drug Administration is cracking down on websites that claim to sell the underlying chemicals of popular diabetes and obesity drugs like Ozempic, Wegovy, and Zepbound, saying that the websites are selling unapproved and misbranded drug products. DBA Helix Chemical Supply and US Chem Labs.
FDA 124
124 FDA 124
124 
Assessing the Accuracy of Pharmaceutical-Sponsored Health Information Online
Pharma Marketing Network
JULY 12, 2023
The internet is a vast resource of information on health and wellness. However, not all of this information is created equal. Some of it is accurate and reliable, while other information may be misleading or even harmful. This is especially true when it comes to pharmaceutical-sponsored health information.
STAT+: Otsuka’s digital treatment for depression cleared by FDA, as pharma tries to crack tricky market
STAT
APRIL 1, 2024
The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition. ” Patients also receive cognitive behavioral therapy.
FDA 135
135 
Health tech company Surescripts picks up ActiveRADAR to expand therapeutic alternatives to prescription drugs
Fierce Healthcare
NOVEMBER 6, 2023
Health information network Surescripts acquired ActiveRADAR to build out therapeutic alternatives for prescription drugs. Health information network Surescripts acquired ActiveRADAR to build out therapeutic alternatives for prescription drugs.
70 
New Research Discovers Impact of NSAIDs on C. Difficile
Pharmacy Times
JULY 26, 2023
The data could inform how non–steroidal anti-inflammatory drug-mediated mitochondrial uncoupling could affect other diseases.
123 
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
STAT
APRIL 28, 2024
The Food and Drug Administration, informed about the imbalance in severe cancer progressions, issued a warning letter to all physicians involved in the study, and is said to be monitoring the situation. Continue to STAT+ to read the full story…
90 
STAT+: IVF doctors demand full details on fluid that grows embryos amid CooperSurgical lawsuits
STAT
MARCH 8, 2024
The Food and Drug Administration asks manufacturers for a list of materials before the media goes on the market, an FDA spokesperson told STAT. Companies will sometimes give clinics this information voluntarily, along with required labeling information like mouse embryo data, instructions for use, and warnings.
Labelling 118
118 
STAT+: Icon acquires HumanFirst to boost support for digital tools in clinical trials
STAT
FEBRUARY 29, 2024
As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions. Continue to STAT+ to read the full story…
Scientists want to put carbon footprints on drugs. But it’s hard to get accurate numbers
STAT
OCTOBER 5, 2023
Anyone picking up a prescription from their pharmacy is used to the reams of paper that typically accompany it: information on safety, storing, and how to use the drug. What if that information also included your medicine’s carbon footprint?
STAT+: Pharmalittle: We’re reading about slow uptake of an Alzheimer’s drug, an opioid lawsuit, and more
STAT
FEBRUARY 14, 2024
Food and Drug Administration fully approved a Biogen treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide , The Boston Globe tell us. About 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month, he added.
90 
Florida’s Prescription Drug Reform Act: What it Means for Florida Pharmacies
Digital Pharmacist
OCTOBER 6, 2023
ConclusionI n July 2023, Florida passed the Prescription Drug Reform Act (Chapter 2023-29). The Prescription Drug Reform Act aims to regulate pharmacy benefit managers (PBMs) and pharmaceutical manufacturers in the state. This information must include applicable network reimbursement IDs. Now, what is this act?
Insurance 105
105 Insurance 105
105 
Annovis looks to advance pivotal Alzheimer’s and Parkinson’s drug studies
Pharmaceutical Technology
OCTOBER 25, 2023
The AD and PD drug aims to reduce the level of neurotoxic proteins, thereby improving information flow across the axonal transport
98 
FDA urged to move faster to fix pulse oximeters for darker-skinned patients
STAT
FEBRUARY 2, 2024
The Food and Drug Administration should move more quickly to ensure pulse oximeters — the ubiquitous devices used to measure blood oxygen — work well in all patients, should better inform clinicians about the devices’ shortcomings in patients with darker skin, and should recall versions that are particularly problematic, patients, (..)
FDA 142
142 FDA 142
142 
Opinion: Patients might finally receive practical information with prescriptions — if the FDA doesn’t blow it
STAT
SEPTEMBER 12, 2023
The Food and Drug Administration knows many of the answers. After years of deliberation, the FDA has proposed giving patients a simple one-pager for every prescription drug with the information needed for safe and effective use. Patients often ask two questions about every medical treatment: Will it help me? Will it hurt me?
FDA 126
126 
STAT+: Federal regulators, scrambling to keep up with AI in health care, team up with industry to set standards
STAT
MARCH 4, 2024
The nonprofit announced that its board of directors will include leaders from the Food and Drug Administration and the Office of the National Coordinator for Health Information Technology — agencies that, until now, have been setting up guardrails for AI in health care on their own.
Hospitals 136
136 
Opinion: How the drug price negotiation program could affect Medicare Part D beneficiaries
STAT
SEPTEMBER 8, 2023
After the recent announcement of the first 10 drugs selected for Medicare price negotiation, much has been discussed about the drugs that were selected and the magnitude of price decreases that can be achieved. The 10 drugs selected in 2023 represent more than 20% of Medicare Part D’s total annual spending on prescription drugs.
117 
STAT+: Many doctors are in the dark about how FDA approves devices and drugs, survey finds
STAT
JANUARY 16, 2024
In her final presentation for health policy class at the University of Chicago, first-year medical student Robin Ji informed her classmates that the Food and Drug Administration does not require randomized controlled trials of most medical devices. Around 41% felt they understood the drug side.
FDA 129
129 
To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA
The FDA Law Blog
SEPTEMBER 19, 2023
Karst — Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny. The six-page statement explains that “Brand drug manufacturers may be harming generic competition through the improper listing of patents in the. Koblitz & Kurt R.
FDA 105
105 
STAT+: Momentum builds for House bill cracking down on Chinese biotechs
STAT
APRIL 26, 2024
biotechnology companies from doing business with a Chinese company that makes key drug ingredients, according to five lobbyists tracking the BIOSECURE Act. national security if they give the Chinese government access to sensitive health information about Americans.
Packaging 82
82 Packaging 82
82 
STAT+: Biden administration makes opening offers in Medicare drug price negotiations
STAT
FEBRUARY 1, 2024
WASHINGTON — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.
STAT+: Leaked version of EFTA-India free trade deal sparks alarm over access to medicines
STAT
FEBRUARY 14, 2024
Specifically, drug manufacturers would be given six years of so-called data exclusivity, which refers to the exclusive rights to the results of preclinical tests and clinical trials for a medicine. This information would not have to be shared with generic companies. As a result, a brand-name drugmaker would obtain an extended monopoly.
119 
DrugGPT: new AI tool could help doctors prescribe medicine in England
The Guardian - Pharmaceutical Industry
MARCH 31, 2024
New tool may offer prescription ‘safety net’ and reduce the 237m medication errors made each year in England Drugs are a cornerstone of medicine, but sometimes doctors make mistakes when prescribing them and patients don’t take them properly. A new AI tool developed at Oxford University aims to tackle both those problems.
72 
STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds
STAT
NOVEMBER 15, 2023
Food and Drug Administration were more frequently invalidated due to information misrepresented or withheld from patent examiners than any other industry sector, according to a new analysis. The patents on medicines and devices approved by the U.S. Between 2004 and 2021, a U.S. Between 2004 and 2021, a U.S.
FDA 112
112 FDA 112
112 
Opinion: A dangerous loophole for drug ads needs to be closed
STAT
JANUARY 26, 2023
A loophole in prescription drug regulation exposes American consumers to false and misleading claims of drug ads via on-line businesses promoting potent drugs without accurate information about their risks and benefits. Many countries prohibit direct-to-consumer advertising of prescription drugs.
Clear that Cabinet Tour ‘24
The FDA Law Blog
APRIL 17, 2024
Drug Take Back Days have made appearances each spring and autumn since 2010. Last October’s Drug Take Back Day removed 600,000 pounds (300 tons) of medication at almost 4,700 collection sites. Additional information about DEA’s National Prescription Drug Take Back Day, including local disposal venues, can be found here.
Opinion: STAT+: Use evidence to support early coverage of gene therapy after accelerated approval
STAT
APRIL 23, 2024
The Food and Drug Administration has approved several gene therapies for rare diseases through the accelerated pathway. in his recent request for information on behalf of the Senate’s Committee on Health, Education, Labor and Pensions (HELP). Bill Cassidy (R-La.)
FDA 84
84 FDA 84
84 
STAT+: House panel passes PBM reforms, ratcheting up chance for passage
STAT
NOVEMBER 15, 2023
WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills. Continue to STAT+ to read the full story…
Insurance 112
112 Insurance 112
112 
DIA 2023: Courtney Granville Discusses Issues Impacting Broader Supply Chains
Pharmaceutical Commerce
JUNE 28, 2023
In an interview with Pharma Commerce Editor, Nicholas Saraceno, Courtney Granville, Director, Scientific Affairs, Drug Information Association, discusses issues impacting broader supply chains.
88 
Let's personalize your content